

December 10, 2021

Company name: Astena Holdings Co., Ltd.
Representative: Keitaro Iwaki, President & CEO
(Stock code: 8095 First Section of TSE)
Inquiries: Hiroyuki Watanabe, Senior General Manager
Administration Division
(TEL +81-3-3279-0481)

Notice Concerning Transfer of Manufacturing and Marketing Approval and Sales and Distribution for “Nizoral® Lotion 2%” in Japan

Astena Holdings Co., Ltd. (the “Company”) hereby announces that the manufacturing and marketing approval and the sales and distribution for Nizoral® Lotion 2% in Japan will be transferred from Janssen Pharmaceutical K.K. (“Janssen”) to the Company’s consolidated subsidiary IWAKI SEIYAKU CO., LTD. (“IWAKI SEIYAKU”) on April 1, 2022. The details are as follows.

Nizoral® Lotion is a lotion with an indication for treatment of ringworm, cutaneous candidiasis, tinea versicolor and seborrheic dermatitis. The lotion was developed as a topical formulation of ketoconazole, which was synthesized by Janssen in Belgium in 1976 as a medication in the imidazole group of antifungal agents with high antifungal activity.

IWAKI SEIYAKU is focused on the manufacturing and marketing of prescription drugs and over-the-counter drugs. For prescription drugs, IWAKI SEIYAKU mainly develops, manufactures and markets generic drugs in the field of dermatology, but Nizoral® Lotion is the first long-listed drug that IWAKI SEIYAKU has handled. Going forward, while aiming to further expand the product lineup, the entire company will strive to provide a stable supply of this product to the market.

Following the transfer, IWAKI SEIYAKU will start marketing, providing and collecting medical information, and carrying out other activities related to this product. Accordingly, for any inquiries, reports of side effects, etc., please contact IWAKI SEIYAKU.

Please note that Janssen’s products will continue to be distributed for some time even after the transfer. We kindly ask for your understanding for any inconvenience this may cause.
